Disitamab Vedotin Toripalimab Survival Urothelial Cancer | GU Oncology Now
Researchers evaluated the use of disitamab vedotin with toripalimab in improving survival in patients with advanced UC.
Related Articles
Benchmarking Photon-Counting Computed Tomography Angiography Against Invasive Assessment of Coronary Stenosis: Implications for Severely Calcified Coronaries
AbstractBackgroundClinical guidelines do not recommend coronary computed tomographic angiography (CTA) in elderly patients or in the presence of heavy coronary calcification. Photon-counting corona…
“Stick and Swap” Technique Through the ReCross Dual-Lumen Microcatheter:
AbstractBackgroundA major limitation of antegrade dissection and re-entry (ADR) is formation of an extraplaque hematoma that can hinder the crossing of coronary chronic total occlusions…
How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs
(Move to …) ABOUT INDUSTRY REPORTS WEBINARS KEYNOTE SPEAKING ADVERTISE SUBSCRIBE / CONTACT
Addressing Elevated Lipoprotein(a): The Importance of Testing At-Risk Patients
Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD1. Read on to learn more about patient populations at risk.
Pegcetacoplan for Kidney Transplant Recipients With Recurrent C3G or IC-MPGN | Docwire News
The NOBLE trial examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN.
Q&A: Guideline-Based Care Often Missing in Polycythemia Vera- Physician’s Weekly
Anthony M. Hunter, MD, discusses study findings showing that many patients with polycythemia vera do not receive treatment in line with NCCN guidelines.
HFSA Pharmacist Webinar: Initiating a Pharmacist Run Heart Failure Clinic | HFSA
Join HFSA for a virtual webinar of panelists discussing career options including Physician Scientist, VA, Industry, and Private Practice, taking place December 10 at 8:00 PM…
New Study Shows Who Benefits Most and When From Eczema Drug Lebrikizumab | Docwire News
Study finds early lebrikizumab response in AD linked to lower inflammation—may guide personalized treatment plans.
CREST Trial Marks New Era for High-Risk NMIBC: Dr. Gordon Brown | GU Oncology Now
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Inside the War on Myeloid Malignancies: Early Clues & Bold Innovations | Blood Cancers Today
Drs. Rahul Banerjee and Uma Borate explore early detection in myeloid malignancies, covering clinical gaps, MRD monitoring, and the promise of AI and liquid biopsy…
